Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck, known as MSD outside of the United States and Canada, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of PREVYMIS® for prophylaxis of cytomegalovirus disease in adult kidney transplant recipients at high risk.